Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.22
-1.1500-0.92%
Post-market: 123.410.1931+0.16%19:30 EDT
Volume:1.48M
Turnover:182.70M
Market Cap:24.98B
PE:15.70
High:124.00
Open:122.66
Low:121.61
Close:124.37
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.59
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.22

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Jun 23

What Incyte (INCY)'s Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

Simply Wall St.
·
Jun 23

Incyte Corp. Stock Rises 5.5%, Outperforms Peers

Dow Jones
·
Jun 23

Incyte price target raised to $105 from $103 at Truist

TIPRANKS
·
Jun 23

Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept

MT Newswires Live
·
Jun 23

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BUZZ-Incyte rises as it settles Medicaid dispute with US government

Reuters
·
Jun 22

Incyte - Plans to Update Financial Guidance to Reflect Settlement Impact at Next Earnings Release - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte: Settlement Was Reached Based on the Unique Facts of Opzelura and Jakafi

THOMSON REUTERS
·
Jun 22

Incyte - CMS Will Not Apply Line Extension Regulation to Opzelura; Incyte Withdraws Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Expects One-Time Non-Cash Benefit of $246 Mln in Q2 Ending June 30, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Announces Agreement With CMS to Resolve Opzelura Medicaid Rebate Litigation - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte settles CMS Opzelura Medicaid rebate dispute, drops lawsuit

Reuters
·
Jun 22

Incyte : Bmo Raises to Market Perform From Underperform; Raises Target Price to $94 From $75

THOMSON REUTERS
·
Jun 22

Incyte Raised to Market Perform From Underperform by BMO Capital

Dow Jones
·
Jun 22

BMO Capital Upgrades Incyte to Market Perform From Underperform, Adjusts PT to $94 From $75

MT Newswires Live
·
Jun 22

Incyte upgraded to Market Perform from Underperform at BMO Capital

TIPRANKS
·
Jun 22

Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks

TIPRANKS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Incyte Japan announces approval of Minjuvi combination for DLBCL

TIPRANKS
·
Jun 19